BradleyJMonkMD

Obstetrics & Gynecology • West Palm Beach, FL

Gynecologic Oncology

Professor, Obstetrics and Gynecology, UA College of Medicine-Phoenix

Join to view full profile

Dr. Monk is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Monk's full profile

Already have an account?

Office
1309 N Flagler Dr
West Palm Beach, FL 33401
Phone+1 561-366-4100

Fax+1 561-366-4189

Summary

Dr. Bradley Monk is an obstetrician/gynecologist in Phoenix, AZ and is affiliated with multiple hospitals in the area, including Valleywise Health, St. Joseph's Hospital and Medical Center, Chandler Regional Medical Center, and Mercy Gilbert Medical Center. He received his medical degree from University of Arizona College of Medicine - Tucson and has been in practice 29 years. He specializes in gynecologic oncology and is experienced in general obstetrics and gynecology and gynecologic oncology.

Education & Training

University of California (Irvine)Residency, Gynecologic Oncology, 1992 - 1995
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Obstetrics and Gynecology, 1988 - 1992
University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 1990 - 1990
University of Arizona College of MedicineClass of 1988

Certifications & Licensure

CA State Medical License 1990 - 2027
FL State Medical License 2019 - 2026
AZ State Medical License 2010 - 2025
NV State Medical License 1998 - 2023
TX State Medical License 1996 - 2018
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2010
America's Top Doctors for Cancer Castle Connolly, 2008-2009
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix Start of enrollment: 2002 Apr 01
Completed
Phase 2
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Start of enrollment: 2003 May 01
Completed
Phase 3
Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 2
Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma Start of enrollment: 2004 Jan 01
Completed
Phase 2
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Start of enrollment: 2007 Jun 01
Completed
Phase 2
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Start of enrollment: 2008 Mar 01
Completed
Phase 2
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2008 Sep 01
Completed
Phase 2
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
Completed
Phase 2
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Mar 01
Completed
Phase 1
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Mar 21
Completed
Phase 2
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection Start of enrollment: 2012 Jan 03
Active, not recruiting
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) Start of enrollment: 2016 May 19
Terminated
Phase 3
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer Start of enrollment: 2021 Mar 01
Withdrawn
Phase 1, Phase 2
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) Start of enrollment: 2019 Feb 15
Completed
Phase 3
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Start of enrollment: 2020 Jul 23
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Ana Oaknin, Bradley J Monk, Andreia Cristina de Melo, Hee Seung Kim, Yong Man Kim
European Journal of Cancer. 2025-01-10
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial can...
Giorgio Valabrega, Matthew A Powell, Sakari Hietanen, Eirwen M Miller, Zoltan Novak
International Journal of Gynecological Cancer. 2025-01-06
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients w...
Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, Kathleen Nadine Moore, Michel Fabbro
International Journal of Gynecological Cancer. 2025-01-06

Lectures

CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer-A phas...
2019 ASCO Annual Meeting - 6/1/2019

Other

The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum
Monk BJ, Birrer MJ
http://www.uptodate.com/contents/the-role-of-angiogenesis-inhibitors-in-epithelial-carcinoma-of-the-
UpToDate, Wolters Kluwer Health - 2013-02-25

Press Mentions

Doublet Maintenance Therapy Does Not Outperform Monotherapy in Ovarian CancerNovember 11th, 2024
Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian CancerSeptember 18th, 2024
Florida Cancer Specialists & Research Institute Contributing to Transformative Cancer Therapies WorldwideSeptember 12th, 2024
Join now to see all